Monograph: |
Ciprofibrate A white or slightly yellow, crystalline powder. Practically insoluble in water; freely soluble in dehydrated alcohol; soluble in toluene. Store in airtight containers. Protect from light.
Adverse Effects and Precautions
As for Bezafibrate.
Interactions
As for Bezafibrate.
Pharmacokinetics
Ciprofibrate is readily absorbed from the gastrointestinal tract; peak plasma concentrations occur within 1 to 4 hours. Ciprofibrate is highly protein bound. It is excreted in the urine as unchanged drug and as glucuronide conjugates. The elimination half-life varies from about 38 to 86 hours in patients on long-term therapy.
Uses and Administration
Ciprofibrate, a fibric acid derivative, is a lipid regulating drug with actions on plasma lipids similar to those of bezafibrate.
It is used to reduce total cholesterol and triglycerides in the management of hyperlipidaemias, including type IIa, type IIb, type III, and type IV hyperlipoproteinaemias. The usual dose is 100 mg daily by mouth. The dose should be reduced in renal impairment.
Administration in renal impairment.
Ciprofibrate is contra-indicated in patients with severe renal impairment. The manufacturer has suggested reducing the dose to 100 mg every other day for patients with moderate renal impairment.
Renal clearance of ciprofibrate was reduced and elimination half-life about doubled in patients with severe renal impairment. Mild renal impairment slowed the urinary excretion of ciprofibrate but not its extent. The clearance of ciprofibrate was unaffected by haemodialysis.
|